Investment Thesis
Envoy Medical is in critical financial distress with negative stockholders' equity of -$7.7M, indicating technical insolvency. The company is burning cash at an alarming rate (-$12.5M operating cash flow) while generating minimal revenue ($166K), demonstrating fundamental operational failure and inability to sustain operations without immediate capital intervention.
Strengths
- Maintains $3.6M cash position providing short-term liquidity runway
- Recent insider Form 4 filings (8 in last 90 days) suggest management engagement
- Modest capital expenditure ($7K) indicates discipline in avoiding additional capex drain
Risks
- Negative stockholders' equity of -$7.7M represents technical insolvency and existential solvency risk
- Severe operating losses (-$15.9M) with revenue declining 28.8% YoY indicates deteriorating core business
- Negative operating cash flow of -$12.5M with only $3.6M cash suggests runway of approximately 3 months at current burn rate
- Current ratio of 0.64x and quick ratio of 0.46x indicate acute liquidity crisis and inability to meet short-term obligations
- Liabilities exceed assets by $7.5M, creating structural insolvency
Key Metrics to Watch
- Cash balance and runway timeline - critical for going concern assessment
- Monthly operating cash burn rate and trajectory
- Revenue stabilization or decline acceleration - fundamental viability indicator
- Restructuring announcements or financing activities indicating recapitalization attempts
- Quarterly cash position trend to assess proximity to insolvency
Financial Metrics
Revenue
166.0K
Net Income
-17.2M
EPS (Diluted)
$-0.97
Free Cash Flow
-12.5M
Total Assets
8.2M
Cash
3.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-9,569.3%
Net Margin
-10,343.4%
ROE
N/A
ROA
-209.9%
FCF Margin
-7,544.0%
Balance Sheet & Liquidity
Current Ratio
0.64x
Quick Ratio
0.46x
Debt/Equity
N/A
Debt/Assets
192.1%
Interest Coverage
-9.99x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T17:54:11.348504 |
Data as of: 2025-09-30 |
Powered by Claude AI